Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis

Özgen Kılıç Erkek; Gülşah Gündoğdu; Davut Akın; Mehmet Alpua; Dilek Sayın; Z. Melek Bor Küçükatay

doi:10.31362/patd.1409090

EN TR

Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis

Abstract

Purpose: Heart damage may develop over time in patients with chronic renal disease (CKD), who are undergoing hemodialysis (HD) treatment. Serum levels of heat shock protein B7 (HSPB7) and tetranectin proteins change following damage to the heart muscle. This study aimed to determine HSPB7 and tetranectin levels in patients with CKD undergoing HD treatment. Materials and methods: The patients aged 30-60 years old, healthy controls (n=30) and HD patients (n=30) participated in the study. Blood samples were taken from healthy subjects who applied to the hospital for check-up and from patients with kidney disease receiving HD treatment. Biochemical parameters were examined from the blood taken. HSPB7 and tetranectin levels from isolated serum samples were determined using measurement kits based on the solid phase sandwich (ELISA) principle. Results: There was no significant difference between the groups in gender, age, glucose and iron (Fe) values of the subjects (p>0.05). Lymphocyte, platelet counts, hemoglobin and albumin values were found to be lower in patient group compared to the control group (p<0.05). Urea, creatine kinase (CK) and C-reactive protein (CRP) values were found to be higher in patient group than in the control group (p<0.05). A significant increase in HSPB7 levels and a significant decrease in tetranectin levels were detected in patient group compared to control group (p<0.001). Conclusions: In this study, the changes detected in HSPB7 and tetranectin levels in with CKD undergoing HD treatment. May be early indicators of the possible development of cardiovascular diseases in patients with renal disease.

Keywords

Hemodialysis, chronic renal disease (CKD), HSPB7, tetranectin

Ethical Statement

Ethical approval was obtained from the Pamukkale University Non-Interventional Ethics Committee with the approval number 13.09.2022/13 and E-60116787-020-263897 dated.

Hemodiyaliz tedavisi alan hastalarda serum Isı Şok Proteini B7 (HSPB7) ve tetranektin düzeylerinin belirlenmesi

Abstract

gelişebilmektedir. Isı şok proteini B7 (HSPB7) ve tetranektin proteinlerinin serum düzeyleri kalp kasında gelişen hasarı takiben değişmektedir. Bu çalışmada, HD tedavisi alan KBH hastalarında HSPB7 ve tetranektin düzeylerinin araştırılması amaçlanmıştır. Gereç ve yöntem: Çalışmaya 30-60 yaş, sağlıklı ve HD hastası denekler katılmış olup iki grup oluşturulmuştur (n=60): Kontrol grubu (n=30) ve Hasta grubu (n=30). Hastaneye check-up için başvuran sağlıklı deneklerden ve böbrek hastalığı olup HD tedavisi alan hastalardan kan örnekleri alınmıştır. Alınan kanlardan biyokimyasal parametreler incelenmiştir. İzole edilen serum örneklerinden HSPB7 ve tetranektin düzeyleri solid faz sandwich (ELİSA) prensibine dayanan ölçüm kitleri kullanılarak belirlenmiştir. Bulgular: Deneklerin cinsiyet, yaş, glukoz ve Demir (Fe) değerlerinde gruplar arasında anlamlı fark saptanmamıştır (p>0,05). Lenfosit, trombosit sayıları, hemoglobin ve albümin değerleri diyaliz hastalarında kontrol grubuna kıyasla düşük bulunmuştur (p<0,05). Diyaliz hastalarında üre, kreatin kinaz ve CRP değerleri sağlıklı kontrol grubuna göre yüksek saptanmıştır (p<0,05). Hastalarda sağlıklı deneklere kıyasla, HSPB7 düzeylerinde anlamlı artış ve tetranektin düzeylerinde ise anlamlı düşüş tespit edilmiştir (p<0,001). Sonuç: Bu çalışmada, diyaliz tedavisi alan KBH hastalarında HSPB7 ve tetranektin düzeylerinde tespit edilen değişimler, böbrek yetmezliği olan hastalarda olası gelişebilecek kardiyovasküler hastalıkların gelişiminin erken göstergesi olabilir.

Keywords

Hemodiyaliz, kronik böbrek hastalığı (KBH), HSPB7, tetranektin

References

1. Okpechi IG, Nthite T, Swanepoel CR. Health-related quality of life in patients on hemodialysis and peritoneal dialysis. Saudi J Kidney Dis Transpl 2013;24:519-526. https://doi.org/10.4103/1319-2442.111036
2. Vaidya SR, Aeddula NR. Chronic Kidney Disease. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. 2022 Oct 24.
3. Elliott DA. Hemodialysis. Clin Tech Small Anim Pract 2000;15:136-148. https://doi.org/10.1053/svms.2000.18297
4. Pedersen JO, Knudsen F, Jersild C. Acute effect of hemodialysis on neutrophil migration: impact on humoral and cellular function. Kidney Int Suppl 1988;24:86-89.
5. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-152. https://doi.org/10.1016/S0140-6736(00)02456-9
6. Li X, Lindholm B. Cardiovascular risk prediction in chronic kidney disease. Am J Nephrol 2022;53:730-739. https://doi.org/10.1159/000528560
7. Cozzolino M, Galassi A, Pivari F, Ciceri P, Conte F. The cardiovascular burden in end-stage renal disease. Contrib Nephrol 2017;191:44-57. https://doi.org/10.1159/000479250
8. Ng CH, Ong ZH, Sran HK, Wee TB. Comparison of cardiovascular mortality in hemodialysis versus peritoneal dialysis. Int Urol Nephrol 2021;53:1363-1371. https://doi.org/10.1007/s11255-020-02683-9
9. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012;380:1649-1661. https://doi.org/10.1016/S0140-6736(12)61272-0
10. Janowska MK, Baughman HER, Woods CN, Klevit RE. Mechanisms of small heat shock proteins. Cold Spring Harb Perspect Biol 2019;11:a034025(e1-22). https://doi.org/10.1101/CSHPERSPECT.A034025

11. Juo LY, Liao WC, Shih YL, Yang BY, Liu AB, Yan YT. HSPB7 interacts with dimerized FLNC and its absence results in progressive myopathy in skeletal muscles. J Cell Sci 2016;129:1661-1670. https://doi.org/10.1242/jcs.179887
12. Sun Y, MacRae TH. The small heat shock proteins and their role in human disease. FEBS J 2005;272:2613-2627. https://doi.org/10.1111/j.1742-4658.2005.04708.x
13. Rusmini P, Cristofani R, Galbiati M, et al. The role of the heat shock protein B8 (HSPB8) in motoneuron diseases. Front Mol Neurosci 2017;21:10:176(e1-9). https://doi.org/10.3389/FNMOL.2017.00176
14. Juo LY, Liao WC, Shih YL, et al. HSPB7 interacts with dimerized FLNC and its absence results in progressive myopathy in skeletal muscles. J Cell Sci 2016;129:1661-1670. https://doi.org/10.1242/jcs.179887
15. Chiu TF, Li CH, Chen CC, et al. Association of plasma concentration of small heat shock protein B7 with acute coronary syndrome. Circ J 2012;76:2226-2233. https://doi.org/10.1253/circj.cj-12-0238
16. Chen FF, Xia YL, Xu CQ, et al. Common variant rs7597774 in ADD2 is associated with dilated cardiomyopathy in Chinese Han population. Int J Clin Exp Med 2015;8:1188-1196.
17. Tanisawa K, Arai Y, Hirose N, et al. Exome-wide association study ıdentifies clec3b missense variant p.s106g as being associated with extreme longevity in east asian populations. J Gerontol A Biol Sci Med Sci 2017;72:309-318. https://doi.org/10.1093/GERONA/GLW074
18. Christensen L, Clemmensen I. Differences in tetranectin immunoreactivity between benign and malignant breast tissue. Histochemistry 1991;95:427-433. https://doi.org/10.1007/BF00315737
19. Arellano Garcia ME, Li R, Liu X, et al. Identification of tetranectin as a potential biomarker for metastatic oral cancer. Int J Mol Sci 2010;11:3106-3121. https://doi.org/10.3390/IJMS11093106
20. Dardé VM, De La Cuesta F, Gil Dones F, Alvarez Llamas G, Barderas MG, Vivanco F. Analysis of the plasma proteome associated with acute coronary syndrome: Does a permanent protein signature exist in the plasma of ACS patients? J Proteome Res 2010;9:4420-4432. https://doi.org/10.1021/pr1002017
21. Ghazavi A, Ganji A, Keshavarzian N, Rabiemajd S, Mosayebi G. Cytokine profile and disease severity in patients with COVID-19. Cytokine 2021;137:155323. https://doi.org/10.1016/j.cyto.2020.155323
22. Khan Z, Pandey M. Role of kidney biomarkers of chronic kidney disease: an update. Saudi J Biol Sci 2014;21:294-299. https://doi.org/10.1016/J.SJBS.2014.07.003
23. Wang Y, Gao L. Inflammation and cardiovascular disease associated with hemodialysis for end-stage renal disease. Front Pharmacol 2022;13:800950(e1-19). https://doi.org/10.3389/FPHAR.2022.800950
24. Alanli R, Kucukay MB, Mursel S, et al. Laboratory test paramaters and echocardiography findings that affect mortality in hemodialysis patients. Ankara Egt Ars Hast Derg 2022;56:74-77. https://doi.org/10.20492/aeahtd.1019834
25. Ma L, Zhao S. Risk factors for mortality in patients undergoing hemodialysis: A systematic review and meta-analysis. Int J Cardiol 2017;238:151-158. https://doi.org/10.1016/j.ijcard.2017.02.095
26. Jaffe AS, Ritter C, Meltzer V, Harter H, Roberts R. Unmasking artifactual increases in creatine kinase isoenzymes in patients with renal failure. J Lab Clin Med 1984;104:193-202.
27. Moro García MA, Mayo JC, Sainz RM, Alonso Arias R. Influence of Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and Oxidative Changes. Front Immunol 2018;9:00339(e1-18). https://doi.org/10.3389/FIMMU.2018.00339
28. Hakim RM, Schafer AI. Hemodialysis-associated platelet activation and thrombocytopenia. Am J Med 1985;78:575-580. https://doi.org/10.1016/0002-9343(85)90398-5
29. Buchanan C, Mohammed A, Cox E, et al. Intradialytic cardiac magnetic resonance imaging to assess cardiovascular responses in a short-term trial of hemodiafiltration and hemodialysis. J Am Soc Nephrol 2017:28:1269-1277. https://doi.org/10.1681/ASN.2016060686
30. Kanda H, Hirasaki Y, Iida T, Kanao Kanda M, Toyama Y, Chiba T, Kunisawa T. Perioperative management of patients with end-stage renal disease. J Cardiothorac Vasc Anesth 2017;31:2251-2267. https://doi.org/10.1053/j.jvca.2017.04.019
31. Morimoto RI. Cell-nonautonomous regulation of proteostasis in aging and disease. Cold Spring Harb Perspect Biol 2020;12:a034074. https://doi.org/10.1101/CSHPERSPECT.A034074
32. Doran P, Gannon J, O’Connell K, Ohlendieck K. Aging skeletal muscle shows a drastic increase in the small heat shock proteins αB-crystallin/HspB5 and cvHsp/HspB7. Eur J Cell Biol 2007;86:629-640. https://doi.org/10.1016/j.ejcb.2007.07.003
33. Muranova LK, Shatov VM, Bukach OV, Gusev NB. Cardio-Vascular Heat Shock Protein (cvHsp, HspB7), an unusual representative of small heat shock protein family. Biochemistry (Moscow) 2021;86:1-11. https://doi.org/10.1134/S0006297921140017
34. Rosenfeld GE, Mercer EJ, Mason CE, Evans T. Small heat shock proteins Hspb7 and Hspb12 regulate early steps of cardiac morphogenesis. Dev Biol 2013;381:389-400. https://doi.org/10.1016/J.YDBIO.2013.06.025
35. Liu L, Zhang X, Qian B, et al. Over-expression of heat shock protein 27 attenuates doxorubicin-induced cardiac dysfunction in mice. Eur J Heart Fail 2007;9:762-769. https://doi.org/10.1016/j.ejheart.2007.03.007
36. Liao WC, Juo LY, Shih YL, Chen YH, Yan YT. HSPB7 prevents cardiac conduction system defect through maintaining intercalated disc integrity. PLoS Genet 2017;13:e1006984. https://doi.org/10.1371/JOURNAL.PGEN.1006984
37. Mogues T, Etzerodt M, Hall C, Engelich G, Graversen JH, Hartshorn KL. Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity. J Biomed Biotechnol 2004;2004:73-78. https://doi.org/10.1155/S1110724304307096
38. Jaquinod M, Las Holtet T, Etzerodt M, Clemmensen I, Thøgersen HC, Roepstorff P. Mass spectrometric characterisation of post-translational modification and genetic variation in human tetranectin. Biol Chem 1999;380:1307-1314. https://doi.org/10.1515/BC.1999.166
39. Yin X, Subramanian S, Hwang SJ, et al. Protein biomarkers of new-onset cardiovascular disease: a prospective study from the Systems Approach to Biomarker Research in Cardiovascular Disease (SABRe CVD) initiative. Arterioscler Thromb Vasc Biol 2014;34:939-945. https://doi.org/10.1161/ATVBAHA.113.302918
40. Chen Y, Han H, Yan X, et al. Tetranectin as a potential biomarker for stable coronary artery disease. Sci Rep 2015;1:17632. https://doi.org/10.1038/SREP17632

Details

Primary Language

English

Subjects

Internal Diseases

Journal Section

Research Article

Authors

Özgen Kılıç Erkek ^*
0000-0001-8037-099X
Türkiye

Gülşah Gündoğdu
0000-0002-9924-5176
Türkiye

Davut Akın
0000-0002-9567-7940
Türkiye

Mehmet Alpua
0000-0002-2359-007X
Türkiye

Dilek Sayın
0000-0003-4022-874X
Türkiye

Z. Melek Bor Küçükatay
0000-0002-9366-0205
Türkiye

Early Pub Date

February 21, 2024

Publication Date

April 1, 2024

Submission Date

January 3, 2024

Acceptance Date

February 19, 2024

Published in Issue

Year 2024 Volume: 17 Number: 2

DOI

https://doi.org/10.31362/patd.1409090

IZ

https://izlik.org/JA22BG66ET

APA

Kılıç Erkek, Ö., Gündoğdu, G., Akın, D., Alpua, M., Sayın, D., & Bor Küçükatay, Z. M. (2024). Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis. Pamukkale Medical Journal, 17(2), 337-345. https://doi.org/10.31362/patd.1409090

AMA

1.Kılıç Erkek Ö, Gündoğdu G, Akın D, Alpua M, Sayın D, Bor Küçükatay ZM. Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis. Pam Med J. 2024;17(2):337-345. doi:10.31362/patd.1409090

Chicago

Kılıç Erkek, Özgen, Gülşah Gündoğdu, Davut Akın, Mehmet Alpua, Dilek Sayın, and Z. Melek Bor Küçükatay. 2024. “Determining the Levels of Serum Heat Shock Protein B7 (HSPB7) and Tetranectin in Patients Undergoing Hemodialysis”. Pamukkale Medical Journal 17 (2): 337-45. https://doi.org/10.31362/patd.1409090.

EndNote

Kılıç Erkek Ö, Gündoğdu G, Akın D, Alpua M, Sayın D, Bor Küçükatay ZM (April 1, 2024) Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis. Pamukkale Medical Journal 17 2 337–345.

IEEE

[1]Ö. Kılıç Erkek, G. Gündoğdu, D. Akın, M. Alpua, D. Sayın, and Z. M. Bor Küçükatay, “Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis”, Pam Med J, vol. 17, no. 2, pp. 337–345, Apr. 2024, doi: 10.31362/patd.1409090.

ISNAD

Kılıç Erkek, Özgen - Gündoğdu, Gülşah - Akın, Davut - Alpua, Mehmet - Sayın, Dilek - Bor Küçükatay, Z. Melek. “Determining the Levels of Serum Heat Shock Protein B7 (HSPB7) and Tetranectin in Patients Undergoing Hemodialysis”. Pamukkale Medical Journal 17/2 (April 1, 2024): 337-345. https://doi.org/10.31362/patd.1409090.

JAMA

1.Kılıç Erkek Ö, Gündoğdu G, Akın D, Alpua M, Sayın D, Bor Küçükatay ZM. Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis. Pam Med J. 2024;17:337–345.

MLA

Kılıç Erkek, Özgen, et al. “Determining the Levels of Serum Heat Shock Protein B7 (HSPB7) and Tetranectin in Patients Undergoing Hemodialysis”. Pamukkale Medical Journal, vol. 17, no. 2, Apr. 2024, pp. 337-45, doi:10.31362/patd.1409090.

Vancouver

1.Özgen Kılıç Erkek, Gülşah Gündoğdu, Davut Akın, Mehmet Alpua, Dilek Sayın, Z. Melek Bor Küçükatay. Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis. Pam Med J. 2024 Apr. 1;17(2):337-45. doi:10.31362/patd.1409090

Pamukkale Medical Journal is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY NC).

Determining the levels of serum Heat Shock Protein B7 (HSPB7) and tetranectin in patients undergoing hemodialysis

Abstract

Keywords

Ethical Statement

Hemodiyaliz tedavisi alan hastalarda serum Isı Şok Proteini B7 (HSPB7) ve tetranektin düzeylerinin belirlenmesi

Abstract

Keywords

References

Details

Primary Language

Subjects

Journal Section

Authors

Early Pub Date

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite